General Information:

Id: 2,533 (click here to show other Interactions for entry)
Diseases: Alzheimer disease - [OMIM]
Mammalia
review
Reference: Di Paolo G and Kim TW(2011) Linking lipids to Alzheimers disease: cholesterol and beyond. Nat. Rev. Neurosci. 12: 284-296 [PMID: 21448224]

Interaction Information:

Comment Reducing membrane cholesterol levels through cholesterol-extracting compounds, such as beta-methyl cyclodextrin (betaMCD), decreases activity of both BACE1 and gamma-secretase, leading to an additive reduction in amyloid-beta generation.
Formal Description
Interaction-ID: 23822

drug/chemical compound

Methyl-beta-cyclodextrin

decreases_quantity of

drug/chemical compound

Cholesterol

Drugbank entries Show/Hide entries for
Comment Reducing membrane cholesterol levels through cholesterol-extracting compounds, such as beta-methyl cyclodextrin (betaMCD), decreases activity of both BACE1 and gamma-secretase, leading to an additive reduction in amyloid-beta generation.
Formal Description
Interaction-ID: 23825

drug/chemical compound

Cholesterol

increases_activity of

gene/protein

BACE1

Drugbank entries Show/Hide entries for Cholesterol or BACE1
Comment Reducing membrane cholesterol levels through cholesterol-extracting compounds, such as beta-methyl cyclodextrin (betaMCD), decreases activity of both BACE1 and gamma-secretase, leading to an additive reduction in amyloid-beta generation.
Formal Description
Interaction-ID: 23826

drug/chemical compound

Cholesterol

increases_activity of

Drugbank entries Show/Hide entries for Cholesterol
Comment Reducing membrane cholesterol levels through cholesterol-extracting compounds, such as beta-methyl cyclodextrin (betaMCD), decreases activity of both BACE1 and gamma-secretase, leading to an additive reduction in amyloid-beta generation.
Formal Description
Interaction-ID: 23827

drug/chemical compound

Cholesterol

affects_quantity of

gene/protein

Amyloid beta peptide

Drugbank entries Show/Hide entries for Cholesterol
Comment Cholesterol depletion decreases the association of BACE1 with lipid rafts, which correlates with decreased amyloidogenic processing of APP.
Formal Description
Interaction-ID: 24061

drug/chemical compound

Cholesterol

affects_processing of

gene/protein

APP

The amyloidogenic processing of APP is affected.
Drugbank entries Show/Hide entries for Cholesterol or APP
Comment Cholesterol depletion decreases the association of BACE1 with lipid rafts, which correlates with decreased amyloidogenic processing of APP.
Formal Description
Interaction-ID: 24063

drug/chemical compound

Cholesterol

affects_activity of

phenotype

amyloidosis

Drugbank entries Show/Hide entries for Cholesterol
Comment Acute cell exposure to cholesterol promotes the co-clustering of APP and BACE1 in lipid raft domains, as well as their rapid endocytosis.
Formal Description
Interaction-ID: 24085

drug/chemical compound

Cholesterol

affects_activity of

process

endocytosis

of APP and BACE1
Drugbank entries Show/Hide entries for Cholesterol
Comment The seeding property of GM1 increases with the ageing process and is facilitated by cholesterol-rich environments, indicating that the process might occur in membrane rafts.
Formal Description
Interaction-ID: 80188

drug/chemical compound

Cholesterol

increases_activity of

drug/chemical compound

Ganglioside GM1

Drugbank entries Show/Hide entries for Cholesterol